Jacob Laubach

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Bortezomib in the management of multiple myeloma
    Jacob P Laubach
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Manag Res 1:107-17. 2009
  2. doi request reprint Multiple myeloma
    Jacob Laubach
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Annu Rev Med 62:249-64. 2011
  3. ncbi request reprint Management of relapsed and relapsed/refractory multiple myeloma
    Jacob P Laubach
    Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Natl Compr Canc Netw 9:1209-16. 2011
  4. ncbi request reprint The evolution and impact of therapy in multiple myeloma
    Jacob P Laubach
    Department of Medical Oncology, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA
    Med Oncol 27:S1-6. 2010
  5. ncbi request reprint Novel therapies in the treatment of multiple myeloma
    Jacob P Laubach
    Harvard Medical School and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 7:947-60. 2009
  6. pmc The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    J P Laubach
    Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA
    Leukemia 23:2222-32. 2009
  7. pmc Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
    Jacob P Laubach
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Leuk Lymphoma 50:694-702. 2009
  8. pmc Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
    Güllü Topal Görgün
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 121:2975-87. 2013
  9. doi request reprint Latest advances and current challenges in the treatment of multiple myeloma
    Anuj Mahindra
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 9:135-43. 2012
  10. ncbi request reprint Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
    Paul G Richardson
    Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Blood 121:1961-7. 2013

Collaborators

Detail Information

Publications28

  1. pmc Bortezomib in the management of multiple myeloma
    Jacob P Laubach
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Manag Res 1:107-17. 2009
    ....
  2. doi request reprint Multiple myeloma
    Jacob Laubach
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Annu Rev Med 62:249-64. 2011
    ..This review highlights important historical landmarks in the field of MM, examines the pathogenesis and clinical manifestations of the disease, and outlines principles of both diagnosis and treatment of MM...
  3. ncbi request reprint Management of relapsed and relapsed/refractory multiple myeloma
    Jacob P Laubach
    Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Natl Compr Canc Netw 9:1209-16. 2011
    ..Moreover, the development of new drug classes based on preclinical rationale and the introduction of next-generation agents is likely to further expand treatment options and improve outcomes for relapsed MM...
  4. ncbi request reprint The evolution and impact of therapy in multiple myeloma
    Jacob P Laubach
    Department of Medical Oncology, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA
    Med Oncol 27:S1-6. 2010
    ..As a result of these developments, clinical outcomes have improved significantly. This review highlights important historic landmarks as well as more recent events that have played an important role in the evolution of myeloma therapy...
  5. ncbi request reprint Novel therapies in the treatment of multiple myeloma
    Jacob P Laubach
    Harvard Medical School and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 7:947-60. 2009
    ..In aggregate, the use of novel therapies in MM has been associated with substantial improvements in patient outcome...
  6. pmc The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    J P Laubach
    Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA
    Leukemia 23:2222-32. 2009
    ..This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease...
  7. pmc Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
    Jacob P Laubach
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Leuk Lymphoma 50:694-702. 2009
    ....
  8. pmc Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
    Güllü Topal Görgün
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 121:2975-87. 2013
    ..Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy...
  9. doi request reprint Latest advances and current challenges in the treatment of multiple myeloma
    Anuj Mahindra
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 9:135-43. 2012
    ..A discussion of the challenges associated with these therapeutic approaches is also presented...
  10. ncbi request reprint Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
    Paul G Richardson
    Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Blood 121:1961-7. 2013
    ..This study is registered at http://www.clinicaltrials.gov as #NCT00833833...
  11. doi request reprint Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells
    Steffen Klippel
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Br J Haematol 159:340-51. 2012
    ..1S cells compared to vehicle-treated mice (P = 0·0046). These studies indicate that jasmonates represent a new, promising strategy to treat MM...
  12. pmc The treatment of multiple myeloma patients not eligible for asct
    Paul Richardson
    Jerome Lipper Multiple Myeloma CenterDana Farber Cancer Institute and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    Mediterr J Hematol Infect Dis 2:e2010009. 2010
    ..Increasingly, novel agents are now being incorporated into therapy, based on the positive findings from clinical trials in this setting, and outcomes have improved accordingly...
  13. ncbi request reprint Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings
    Paul G Richardson
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School Boston, Boston, MA, USA
    Br J Haematol 154:755-62. 2011
    ....
  14. doi request reprint Clinical translation in multiple myeloma: from bench to bedside
    Jacob Laubach
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA Department of Medicine, Harvard Medical School, Boston, MA Electronic address
    Semin Oncol 40:549-53. 2013
    ..This review highlights the evolution of drug development in MM, the manner in which preclinical models have contributed to the process of drug discovery, and important insights gained during the current era of MM drug development. ..
  15. doi request reprint New proteasome inhibitors in myeloma
    Panisinee Lawasut
    Division of Hematologic Oncology, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Mayer 228, Boston, MA 02215, USA
    Curr Hematol Malig Rep 7:258-66. 2012
    ..All of these second-generation PIs demonstrate encouraging anti-MM activity and appear to reduce the incidence of PN, with clinical trials ongoing...
  16. ncbi request reprint Tailoring treatment for multiple myeloma patients with relapsed and refractory disease
    Paul G Richardson
    Harvard Medical School, Jerome Lipper Center for Multiple Myeloma, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncology (Williston Park) 24:22-9. 2010
    ..Additional clinical challenges discussed in this article are renal dysfunction, extramedullary disease, and advanced bone disease. Finally, participation in clinical trials is especially encouraged in this patient population...
  17. doi request reprint Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
    Irene M Ghobrial
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 12:263-72. 2011
    ..Our aim was to assess the response and safety of the combination of temsirolimus (an mTOR inhibitor) and bortezomib in patients with relapsed or refractory multiple myeloma...
  18. pmc Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Blood 119:e131-8. 2012
    ..This study provides a framework to identify novel immunomodulatory agents and to prioritize compounds for clinical development on the basis of their effect on antitumor immunity...
  19. doi request reprint Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 29:4243-9. 2011
    ..Clinical data suggest that perifosine in combination with dexamethasone has activity in relapsed or relapsed/refractory MM...
  20. pmc Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Cancer Res 19:3640-8. 2013
    ..We report on the results of a phase II trial in which patients underwent vaccination following autologous stem cell transplantation (ASCT) to target minimal residual disease...
  21. pmc Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
    Paul Richardson
    Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Core Evid 4:215-45. 2010
    ..Emerging evidence supports the ongoing investigation of lenalidomide in combination with low-dose dexamethasone, and in other combinations including bortezomib, for use both in relapsed, refractory, and newly diagnosed MM...
  22. pmc Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
    Douglas W McMillin
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute Department of Medicine, Harvard Medical School, Boston Novartis Institutes for BioMedical Research, Cambridge, MA 02115, USA
    Br J Haematol 152:420-32. 2011
    ..These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM...
  23. pmc Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
    Jana Jakubikova
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA
    Blood 117:4409-19. 2011
    ..Our studies demonstrate a novel mechanism of action for lenalidomide, namely targeting SP fraction, providing the framework for new therapeutic strategies targeting subpopulations of MM cells including presumptive stem cells...
  24. ncbi request reprint Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia
    Paul G Richardson
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 8:S4-S12. 2010
    ..Regular screening and monitoring, combined with patient education and effective management strategies, can reduce the risk of these treatment-related complications, as well as their consequences...
  25. pmc Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Semin Hematol 46:166-75. 2009
    ....
  26. doi request reprint Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 29:1916-23. 2011
    ..This review discusses these challenges, as well as potential strategies to address them, with the aim of making significant improvement in the clinical outcome of patients with MM...
  27. pmc Lenalidomide for the treatment of relapsed and refractory multiple myeloma
    Niels Wcj van de Donk
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer Manag Res 4:253-68. 2012
    ..This is accompanied by recommendations of how to manage and prevent adverse events associated with lenalidomide-based therapy...
  28. pmc The spectrum of kidney involvement in lymphoma: a case report and review of the literature
    Lisa J Cohen
    Nephrology Division, Brigham and Women s Hospital, Boston, MA, USA
    Am J Kidney Dis 56:1191-6. 2010
    ..We discuss a case of non-Hodgkin lymphoma and associated kidney failure from several distinct malignancy-related mechanisms and review the spectrum of lymphoma-related kidney involvement...